These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 27865185)
1. A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality? Rossello X; Yellon DM Int J Cardiol; 2017 Feb; 228():198-200. PubMed ID: 27865185 [TBL] [Abstract][Full Text] [Related]
2. [Cardiovascular and renal protection of patients with type 2 diabetes : focus after EMPA-REG OUTCOME and LEADER]. Scheen AJ; Piérard L; Krzesinski JM; Paquot N Rev Med Liege; 2016 Sep; 71(9):376-381. PubMed ID: 28383832 [TBL] [Abstract][Full Text] [Related]
3. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus. Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264 [TBL] [Abstract][Full Text] [Related]
4. [SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?]. Scheen AJ; Paquot N Rev Med Liege; 2018 Jan; 73(1):43-50. PubMed ID: 29388411 [TBL] [Abstract][Full Text] [Related]
5. [Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER]. Scheen AJ; Wallemacq C; Jandrain B; Ernest P Rev Med Suisse; 2016 Aug; 12(527):1370-1375. PubMed ID: 28671791 [TBL] [Abstract][Full Text] [Related]
6. Usefulness of Empagliflozin Versus Liraglutide for Prevention of Cardiovascular Mortality. Arbel R; Hammerman A; Azuri J Am J Cardiol; 2018 Sep; 122(6):981-984. PubMed ID: 30075890 [TBL] [Abstract][Full Text] [Related]
7. [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system]. Fiorentino TV; Sesti G G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):13S-19. PubMed ID: 28151517 [TBL] [Abstract][Full Text] [Related]
8. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Kaul S Diabetes Care; 2017 Jul; 40(7):821-831. PubMed ID: 28637887 [TBL] [Abstract][Full Text] [Related]
9. After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes? Schatz H Exp Clin Endocrinol Diabetes; 2016 Sep; 124(8):459-460. PubMed ID: 27701709 [TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Events, Acute Hospitalizations, and Mortality in Patients With Type 2 Diabetes Mellitus Who Initiate Empagliflozin Versus Liraglutide: A Comparative Effectiveness Study. Thomsen RW; Knudsen JS; Kahlert J; Baggesen LM; Lajer M; Holmgaard PH; Vedin O; Ustyugova A; Sørensen HT J Am Heart Assoc; 2021 Jun; 10(11):e019356. PubMed ID: 34032121 [TBL] [Abstract][Full Text] [Related]
11. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B; Wanner C; Lachin JM; Fitchett D; Bluhmki E; Hantel S; Mattheus M; Devins T; Johansen OE; Woerle HJ; Broedl UC; Inzucchi SE; N Engl J Med; 2015 Nov; 373(22):2117-28. PubMed ID: 26378978 [TBL] [Abstract][Full Text] [Related]
12. Novel Antidiabetic Therapies and Cardiovascular Risk Reduction: The Role of the Noninferiority Trial. Thompson J; Schacht S; Rothenberg F Cardiol Clin; 2019 Aug; 37(3):335-343. PubMed ID: 31279427 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Abdul-Ghani M; DeFronzo RA; Del Prato S; Chilton R; Singh R; Ryder REJ Diabetes Care; 2017 Jul; 40(7):813-820. PubMed ID: 28637886 [TBL] [Abstract][Full Text] [Related]
15. London buses: A cardiovascular outcome trial equivalent? Grant PJ Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327 [No Abstract] [Full Text] [Related]
16. Practice pearl: liraglutide and cardiovascular and renal events in type 2 diabetes. Guthrie R Postgrad Med; 2018 Mar; 130(2):154-158. PubMed ID: 29350569 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. Ramos M; Ustyugova A; Hau N; Lamotte M J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253 [No Abstract] [Full Text] [Related]
18. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]. Scheen AJ Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271 [TBL] [Abstract][Full Text] [Related]
19. Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics. Scheen AJ Diabetes Metab; 2016 Sep; 42(4):224-33. PubMed ID: 27291329 [TBL] [Abstract][Full Text] [Related]
20. Empagliflozin: a new treatment option for patients with type 2 diabetes mellitus. Dailey GE Drugs Today (Barc); 2015 Sep; 51(9):519-35. PubMed ID: 26488032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]